SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
May 14, 2003
-------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 0-15190 13-3159796
---------------- ------- --------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation) File Number) Identification No.)
58 SOUTH SERVICE ROAD
MELVILLE, NY 11747
-----------------------------
(Address of principal executive offices)
(631) 962-2000
--------- ---------------
(Registrant's telephone number, including area code)
N/A
------------
(Former name or former address,
if changed since last report.)
ITEM 9. REGULATION FD DISCLOSURES
The following information is intended to be included under "Item 12.
Results of Operations and Financial Condition" and is included under this Item 9
in accordance with SEC Release No. 33-8216.
On May 14, 2003, OSI Pharmaceuticals, Inc. (the "Company") issued a
press release regarding its financial results for the quarter ended March 31,
2003. The Company's press release is attached as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated by reference herein.
The information in this Current Report on Form 8-K and the Exhibit
attached hereto shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933 of the Exchange Act, regardless of
any general incorporation language of such filing.
ITEM 7. EXHIBITS
EXHIBIT NO. DESCRIPTION
99.1 Press release, dated May 14, 2003.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: May 14, 2003 OSI PHARMACEUTICALS, INC.
By: /s/ Robert L. Van Nostrand
-------------------------------------
Robert L. Van Nostrand
Vice President and Chief Financial
Officer (Principal Financial Officer)
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
99.1 Press release, dated May 14, 2003.